| Date Filed | Type | Description |
| 09/28/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 08/15/2023 |
SC 13G
| Propel Bio Management, LLC reports a 5.4% stake in EIGER BioPharmaceuticals, Inc. |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 07/28/2023 |
8-K
| Quarterly results |
| 07/07/2023 |
SC 13G/A
| BlackRock Inc. reports a 2.1% stake in EIGER BIOPHARMACEUTICALS INC |
| 07/06/2023 |
4
| Apelian David (CEO) has filed a Form 4 on Eiger BioPharmaceuticals, Inc.|
Txns:
| Granted 750,000 options to buy
@ $0.729, valued at
$546.8k
|
|
| 06/30/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/26/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/26/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/26/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/18/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 04/14/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 04/14/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 04/14/2023 |
8-K
| Quarterly results |
| 03/21/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/17/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/16/2023 |
8-K
| Quarterly results |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/03/2023 |
4
| Sachdev Amit (Director) has filed a Form 4 on Eiger BioPharmaceuticals, Inc.|
Txns:
| Granted 28,000 options to buy
@ $1.705, valued at
$47.7k
|
|
| 03/03/2023 |
4
| Loh Evan (Director) has filed a Form 4 on Eiger BioPharmaceuticals, Inc.|
Txns:
| Granted 28,000 options to buy
@ $1.705, valued at
$47.7k
|
|
| 03/03/2023 |
4
| Murray Christine (Director) has filed a Form 4 on Eiger BioPharmaceuticals, Inc.|
Txns:
| Granted 28,000 options to buy
@ $1.705, valued at
$47.7k
|
|
| 03/03/2023 |
4
| Glenn Jeffrey S (Director) has filed a Form 4 on Eiger BioPharmaceuticals, Inc.|
Txns:
| Granted 28,000 options to buy
@ $1.705, valued at
$47.7k
|
|
| 03/03/2023 |
4
| Sablich Kim (Director) has filed a Form 4 on Eiger BioPharmaceuticals, Inc.|
Txns:
| Granted 28,000 options to buy
@ $1.705, valued at
$47.7k
|
|
| 03/03/2023 |
4
| Kelly-Croswell Lisa (Director) has filed a Form 4 on Eiger BioPharmaceuticals, Inc.|
Txns:
| Granted 28,000 options to buy
@ $1.705, valued at
$47.7k
|
|
| 03/03/2023 |
4
| Mayer Eldon C. III (Ex VP & Chief Commerc. Officer) has filed a Form 4 on Eiger BioPharmaceuticals, Inc.|
Txns:
| Granted 98,000 options to buy
@ $1.705, valued at
$167.1k
|
|
| 03/03/2023 |
4
| Dietz Thomas John (Director) has filed a Form 4 on Eiger BioPharmaceuticals, Inc.|
Txns:
| Granted 40,000 options to buy
@ $1.705, valued at
$68.2k
|
|
| 02/14/2023 |
SC 13G/A
| 683 Capital Management, LLC reports a 7.1% stake in Eiger BioPharmaceuticals, Inc. |
| 02/10/2023 |
8-K
| Quarterly results |
| 02/09/2023 |
SC 13G/A
| ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 0% stake in Eiger BioPharmaceuticals, Inc. |
| 02/06/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
|